Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab versus paclitaxel in previously treated advanced gastric or gastroesophageal junction adenocarcinoma
2014-005241-45Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Pembrolizumab with Paclitaxel (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Feb 2015; status: completed.
02
Drugs
pembrolizumabpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2014-005241-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005241-45.